This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
18


nanotimes


Companies Facts


discharge capabilities,” said Dr. Rick Rocheleau, UH- HNEI Director. “These characteristics are expected to help meet the integration challenges of high-penetra- tion solar energy sources.”


Altairnano had closed on a Share Subscription Ag- reement with Canon Investment Holdings Limited (Canon), through its affiliate, Energy Storage Techno- logy (China) Group Limited (EST). Under the terms of the agreement, Altairnano issued 37,036,807 com- mon shares to EST at $1.5528 per share, providing $57.5 million in proceeds to Altairnano. Following the closing of this transaction, there are 69,452,487 Altairnano common shares outstanding.


http://www.altairnano.com


June 30, 2011. Financial highlights for the second quarter include:


A


• 18% growth in Development/Small Scale Manufac- turing contract revenue over second quarter 2010;


• 21% growth in Large Scale Manufacturing contract revenue over second quarter 2010;


• Received $3 million milestone payment resulting from AMRI’s collaboration with Bristol-Myers Squibb (BMS) for the initiation of a phase II study.


Total revenue for the second quarter of 2011 was $53.9 million, an increase of 9% compared to total revenue of $49.5 million reported in the second quarter of 2010. Total contract revenue for the se- cond quarter of 2011 was $43.5 million, an increase of 7% compared to total contract revenue of $40.7


MRI (NASDAQ: AMRI) reported financial and operating results for the second quarter ended


million reported in the second quarter of 2010. Total contract revenue encompasses revenue from AMRI’s Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing busi- ness components.


Total revenue for the six-month period ended June 30, 2011 was $110.8 million, an increase of $12.0 million or 12% compared to $98.8 million for the same period in 2010. Total contract revenue for the first six months of 2011 was $86.4 million, an incre- ase of $6.8 million or 9% from $79.6 million for the same period in 2010.


Moreover, Takeshi Yura, Ph.D., has been promoted to senior director of drug discovery services at its Singapore subsidiary.


http://www.amriglobal.com


in the current development of a novel spin process for making high performance fibers from AMSilk’s spider silk proteins. AMSilk is the first company able to deliver sufficient spider silk material for applica- tions development. AMSilk’s spider silk is inspired by the natural silk from spiders and produced through biotechnology with an industrial production plat- form.


A http://www.amsilk.com A


PI Technologies Corp. (NASDAQ: ATNY; API), announced the availability of its newest techno-


MSilk and the Fraunhofer Institute for Applied Polymer Research (IAP), Germany, join forces


11-08 :: August 2011


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103